| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $1,263,299 | 5 | 100 |
| Thornberry Nancy | director | 0 | $0 | 1 | $261,929 | $-261,929 |
| Schuth Alexander O. | COFO and Secretary | 0 | $0 | 3 | $420,604 | $-420,604 |
| Watts Ryan J. | President and CEO | 0 | $0 | 1 | $580,767 | $-580,767 |
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Over the last 12 months, insiders at Denali Therapeutics Inc. have bought $0 and sold $1.26M worth of Denali Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Denali Therapeutics Inc. have bought $0 and sold $7.61M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 550,000 shares for transaction amount of $9.9M was made by BRATTON DOUGLAS K (10 percent owner) on 2017‑12‑12.
| 2026-09-02 | Sale | Thornberry Nancy | director | 11,439 0.0072% | $22.90 | $261,929 | -2.49% | |
| 2026-09-01 | Sale | Schuth Alexander O. | COFO and Secretary | 2,768 0.0018% | $23.44 | $64,882 | -3.12% | |
| 2026-08-11 | Sale | Schuth Alexander O. | COFO and Secretary | 2,857 0.0018% | $25.07 | $71,625 | -1.38% | |
| 2026-01-06 | Sale | Watts Ryan J. | President and CEO | 35,198 0.0232% | $16.50 | $580,767 | +21.15% | |
| 2026-01-06 | Sale | Schuth Alexander O. | COFO and Secretary | 17,218 0.0114% | $16.50 | $284,097 | +21.15% | |
| 2025-08-13 | Sale | Ho Carole | Chief Medical Officer | 806 0.0005% | $14.64 | $11,800 | +30.86% | |
| 2025-08-12 | Sale | Schuth Alexander O. | COFO and Secretary | 2,937 0.002% | $13.58 | $39,884 | +46.37% | |
| 2025-08-12 | Sale | Ho Carole | Chief Medical Officer | 2,937 0.002% | $13.58 | $39,884 | +46.37% | |
| 2025-07-09 | Sale | Watts Ryan J. | President and CEO | 495,282 0.3409% | $15.00 | $7.43M | +21.07% | |
| 2025-01-07 | Sale | Watts Ryan J. | President and CEO | 7,650 0.0052% | $20.81 | $159,197 | -28.26% | |
| 2025-01-07 | Sale | Schuth Alexander O. | COFO and Secretary | 2,907 0.002% | $20.81 | $60,495 | -28.26% | |
| 2025-01-07 | Sale | Ho Carole | Chief Medical Officer | 2,907 0.002% | $20.81 | $60,495 | -28.26% | |
| 2025-01-07 | Sale | Krognes Steve E. | director | 3,339 0.0023% | $20.81 | $69,485 | -28.26% | |
| 2025-01-06 | Sale | Watts Ryan J. | President and CEO | 29,266 0.0208% | $20.22 | $591,759 | -23.34% | |
| 2025-01-06 | Sale | Schuth Alexander O. | COFO and Secretary | 12,255 0.0087% | $20.22 | $247,796 | -23.34% | |
| 2025-01-06 | Sale | Ho Carole | Chief Medical Officer | 12,255 0.0087% | $20.22 | $247,796 | -23.34% | |
| 2025-01-02 | Sale | SATO VICKI L | director | 3,080 0.0021% | $20.91 | $64,403 | -27.09% | |
| 2024-12-31 | Sale | Krognes Steve E. | director | 30,000 0.0207% | $20.25 | $607,500 | -25.44% | |
| 2024-11-11 | Sale | Schenkein David P | director | 59,441 0.0421% | $32.51 | $1.93M | -51.88% | |
| 2024-11-07 | Sale | Schuth Alexander O. | COFO and Secretary | 15,558 0.0109% | $29.91 | $465,286 | -48.67% |
| Watts Ryan J. | President and CEO | 296833 0.187% | $6.61M | 0 | 67 | |
| Schuth Alexander O. | COFO and Secretary | 278995 0.1758% | $6.22M | 0 | 73 | |
| Thornberry Nancy | director | 19686 0.0124% | $438,604.08 | 0 | 1 | |
| BRATTON DOUGLAS K | 10 percent owner | 9984836 6.2913% | $222.46M | 1 | 12 | <0.0001% |
| Tessier-Lavigne Marc | director | 1870356 1.1785% | $41.67M | 0 | 17 | |
| Ho Carole | Chief Medical Officer | 216585 0.1365% | $4.83M | 0 | 66 | |
| SATO VICKI L | director | 107976 0.068% | $2.41M | 0 | 28 | |
| Krognes Steve E. | director | 25757 0.0162% | $573,865.96 | 0 | 24 | |
| Cook Jennifer E. | director | 20038 0.0126% | $446,446.64 | 0 | 1 | |
| Schenkein David P | director | 9220 0.0058% | $205,421.60 | 0 | 5 |
$586,486,795 | 47 | 4.28% | $3.73B | |
$151,136,640 | 31 | -1.41% | $3.49B | |
$1,603,489 | 30 | 98.90% | $2.64B | |
$137,434,288 | 25 | 37.98% | $2.99B | |
$169,745,779 | 25 | 31.94% | $3.92B | |
$69,132,919 | 24 | -22.11% | $2.73B | |
$73,814,940 | 15 | -4.77% | $2.6B | |
$50,004,159 | 12 | 75.04% | $3.79B | |
$18,336,420 | 12 | 24.03% | $3.67B | |
$819,080 | 11 | 30.39% | $2.97B | |
$1,741,093 | 10 | 31.47% | $4.07B | |
$1,248,715 | 10 | 5.66% | $3.39B | |
$45,445,266 | 9 | -24.96% | $3.79B | |
$32,575,266 | 8 | 37.03% | $3.91B | |
$3,200,000 | 5 | -11.36% | $4.17B | |
$666,380 | 5 | -16.60% | $2.96B | |
$24,000,085 | 4 | 33.26% | $3.04B | |
Denali Therapeutics Inc. (DNLI) | $9,900,000 | 1 | -7.19% | $3.54B |
$5,000,000 | 1 | -22.84% | $3.89B |
| Increased Positions | 141 | +52.81% | 24M | +16.77% |
| Decreased Positions | 112 | -41.95% | 12M | -8.57% |
| New Positions | 53 | New | 5M | New |
| Sold Out Positions | 38 | Sold Out | 2M | Sold Out |
| Total Postitions | 296 | +10.86% | 152M | +8.19% |
| Blackrock, Inc. | $199,952.00 | 7.88% | 12.29M | +236,281 | +1.96% | 2025-09-30 |
| Vanguard Group Inc | $195,125.00 | 7.69% | 11.99M | +182,183 | +1.54% | 2025-09-30 |
| Baillie Gifford & Co | $188,595.00 | 7.43% | 11.59M | -363,738 | -3.04% | 2025-09-30 |
| Fmr Llc | $103,157.00 | 4.06% | 6.34M | -1M | -15.89% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $91,739.00 | 3.61% | 5.64M | +2M | +73.66% | 2025-09-30 |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Ame | $88,916.00 | 3.5% | 5.47M | -797,240 | -12.73% | 2025-09-30 |
| State Street Corp | $88,904.00 | 3.5% | 5.46M | +946,267 | +20.94% | 2025-09-30 |
| Temasek Holdings (Private) Ltd | $87,139.00 | 3.43% | 5.36M | 0 | 0% | 2025-09-30 |
| Capital Research Global Investors | $77,459.00 | 3.05% | 4.76M | +10,279 | +0.22% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $74,327.00 | 2.93% | 4.57M | -2M | -30.6% | 2025-09-30 |